---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-281920"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:20:47.047479+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio Q3 2022: cash $85.9M; CABA-201 IND submission planned 1H 2023; MuSK-CAART ODD granted

## Summary
- Q3 2022 R&D expenses $8.2M, G&A $3.6M; cash and investments $85.9M, down from $122.2M at Dec 31, 2021.
- Obtained exclusive worldwide license from IASO Bio for CD19 binder used in CABA-201, a fully human CD19-CAR T candidate; IND submission planned 1H 2023.
- FDA granted Orphan Drug Designation to MuSK-CAART for MuSK- myasthenia gravis; first-in-human trial initiation expected Q4 2022.
- Updated DesCAARTes interim data shows favorable safety; combination cohort (DSG3-CAART + IVIg/cyclophosphamide) 1-month data expected Q1 2023.
- Cash runway through Q2 2024; initial CABA-201 clinical data expected by 1H 2024.

## SEC filing metadata
- accession: 0001193125-22-281920
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312522281920/0001193125-22-281920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312522281920/d397150d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-281920
- JSON: https://secwatch.observer/filing/0001193125-22-281920.json
- Plain text: https://secwatch.observer/filing/0001193125-22-281920.txt

## Key facts
- Earnings Releases
  Cabaletta Bio, Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759138/000119312522281920/0001193125-22-281920-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.